Dacarbazine

Dacarbazine Manufacturers

• Teva Parenteral Medicines, Inc
  

  ×

  Dacarbazine | Supervalu Inc

  

  ---

  • shake well before using • adults and children 12 years and older: take 2 to 4 teaspoonsful two times a day or as directed by a physician • do not take more than 8 teaspoonsful in 24 hours or use the maximum dosage for more than 2 weeks • children under 12 years: consult a physician

  Close
  No Recall

  More Info
• Hospira Worldwide, Inc.
  

  ×

  Dacarbazine | Hospira Worldwide, Inc.

  

  ---

  Malignant Melanoma: The recommended dosage is 2 to 4.5 mg/kg/day for 10 days. Treatment may be repeated at 4 week intervals.

  An alternate recommended dosage is 250 mg/square meter body surface/day IV for 5 days. Treatment may be repeated every 3 weeks.

  Hodgkin’s Disease: The recommended dosage of Dacarbazine for Injection in the treatment of Hodgkin’s disease is 150 mg/square meter body surface/day for 5 days, in combination with other effective drugs. Treatment may be repeated every 4 weeks. An alternative recommended dosage is 375 mg/square meter body surface on day 1, in combination with other effective drugs, to be repeated every 15 days.

  Dacarbazine for Injection 200 mg/vial is reconstituted with 19.7 mL of Sterile Water for Injection, USP. The resulting solution contains 10 mg/mL of dacarbazine having a pH of 3.0 to 4.0. The calculated dose of the resulting solution is drawn into a syringe and administered only intravenously.

  The reconstituted solution may be further diluted with 5% dextrose injection, USP or sodium chloride injection, USP and administered as an intravenous infusion.

  After reconstitution and prior to use, the solution in the vial may be stored at 4°C for up to 72 hours or at normal room conditions (temperature and light) for up to 8 hours. If the reconstituted solution is further diluted in 5% dextrose injection, USP or sodium chloride injection, USP, the resulting solution may be stored at 4°C for up to 24 hours or at normal room conditions for up to 8 hours.

  Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published1-7. There is no general agreement that all the procedures recommended in the guidelines are necessary or appropriate.

  Close
  No Recall

  More Info
• App Pharmaceuticals, Llc
  

  ×

  Dacarbazine | App Pharmaceuticals, Llc

  

  ---

  Malignant Melanoma
  

  The recommended dosage is 2 to 4.5 mg/kg/day for 10 days.  Treatment may be repeated at 4 week intervals.2

  An alternate recommended dosage is 250 mg/square meter body surface/day I.V. for 5 days.  Treatment may be repeated every 3 weeks.3,4

  Hodgkin's Disease
  

  The recommended dosage of Dacarbazine for Injection, USP in the treatment of Hodgkin’s disease is 150 mg/square meter body surface/day for 5 days, in combination with other effective drugs.  Treatment may be repeated every 4 weeks.5  An alternative recommended dosage is 375 mg/square meter body surface on day 1, in combination with other effective drugs, to be repeated every 15 days.6

  Dacarbazine for Injection, USP 100 mg/vial and 200 mg/vial are reconstituted with 9.9 mL and 19.7 mL, respectively, of Sterile Water for Injection, USP.  The resulting solution contains 10 mg/mL of dacarbazine having a pH of 3.0 to 4.0.  The calculated dose of the resulting solution is drawn into a syringe and administered only intravenously.

  The reconstituted solution may be further diluted with 5% Dextrose Injection or Sodium Chloride Injection and administered as an intravenous infusion.

  After reconstitution and prior to use, the solution in the vial may be stored at 4°C for up to 72 hours or at normal room conditions (temperature and light) for up to 8 hours.  If the reconstituted solution is further diluted in 5% Dextrose Injection or Sodium Chloride Injection, the resulting solution may be stored at 4°C for up to 24 hours or at normal room conditions for up to 8 hours.

  Procedures for proper handling and disposal of anticancer drugs should be considered.  Several guidelines on this subject have been published.7-13  There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.

  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

  Malignant Melanoma
  

  The recommended dosage is 2 to 4.5 mg/kg/day for 10 days.  Treatment may be repeated at 4 week intervals.2

  An alternate recommended dosage is 250 mg/square meter body surface/day I.V. for 5 days.  Treatment may be repeated every 3 weeks.3,4

  Hodgkin's Disease
  

  The recommended dosage of Dacarbazine for Injection, USP in the treatment of Hodgkin’s disease is 150 mg/square meter body surface/day for 5 days, in combination with other effective drugs.  Treatment may be repeated every 4 weeks.5  An alternative recommended dosage is 375 mg/square meter body surface on day 1, in combination with other effective drugs, to be repeated every 15 days.6

  Dacarbazine for Injection, USP 100 mg/vial and 200 mg/vial are reconstituted with 9.9 mL and 19.7 mL, respectively, of Sterile Water for Injection, USP.  The resulting solution contains 10 mg/mL of dacarbazine having a pH of 3.0 to 4.0.  The calculated dose of the resulting solution is drawn into a syringe and administered only intravenously.

  The reconstituted solution may be further diluted with 5% Dextrose Injection or Sodium Chloride Injection and administered as an intravenous infusion.

  After reconstitution and prior to use, the solution in the vial may be stored at 4°C for up to 72 hours or at normal room conditions (temperature and light) for up to 8 hours.  If the reconstituted solution is further diluted in 5% Dextrose Injection or Sodium Chloride Injection, the resulting solution may be stored at 4°C for up to 24 hours or at normal room conditions for up to 8 hours.

  Procedures for proper handling and disposal of anticancer drugs should be considered.  Several guidelines on this subject have been published.7-13  There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.

  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

  Close
  No Recall

  More Info